PT - JOURNAL ARTICLE AU - Shoaibi, Azadeh AU - Matuska, Kathryn AU - Lloyd, Patricia C. AU - Wong, Hui Lee AU - Gruber, Joann F. AU - Clarke, Tainya C. AU - Cho, Sylvia AU - Lassman, Emily AU - Lyu, Hai AU - McEvoy, Rowan AU - Wan, Zhiruo AU - Hu, Mao AU - Akhtar, Sandia AU - Jiao, Yixin AU - Chillarige, Yoganand AU - Beachler, Daniel AU - Secora, Alex AU - Selvam, Nandini AU - Djibo, Djeneba Audrey AU - McMahill Walraven, Cheryl N AU - Seeger, John D. AU - Amend, Kandace L. AU - Song, Jennifer AU - Clifford, Robin AU - Kelman, Jeffrey A. AU - Forshee, Richard A. AU - Anderson, Steven A. TI - Risk of Adverse Events Following Monovalent Third or Booster Dose of COVID-19 mRNA Vaccination in U.S. Adults Ages 18 Years and Older AID - 10.1101/2024.02.20.24303089 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.20.24303089 4099 - http://medrxiv.org/content/early/2024/02/27/2024.02.20.24303089.short 4100 - http://medrxiv.org/content/early/2024/02/27/2024.02.20.24303089.full AB - Background The U.S. FDA authorized the monovalent third primary series or booster doses of COVID-19 mRNA vaccines in August 2021 for persons 18 years and older. Monitoring of outcomes following updated authorizations is critical to evaluate vaccine safety and can provide early detection of rare adverse events (AEs) not identified in pre-licensure trials.Methods We evaluated the risk of 17 AEs following third doses of COVID-19 mRNA vaccines from August 2021 through early 2022 among adults aged 18-64 years in three commercial databases (Optum, Carelon Research, CVS Health) and adults aged >65 years in Medicare Fee-For-Service. We compared observed AE incidence rates to historical (expected) rates prior to the pandemic, estimated incidence rate ratios (IRRs) for the Medicare database and pooled IRR across the three commercial databases. Analyses were also stratified by prior history of COVID-19 diagnosis. Estimates exceeding a pre-defined threshold were considered statistical signals.Results Four AEs met the threshold for statistical signals for BNT162b2 and mRNA-1273 vaccines including Bell’s Palsy and pulmonary embolism in Medicare, and anaphylaxis and myocarditis/pericarditis in commercial databases. Nine AEs and three AEs signaled among adults with and without prior COVID-19 diagnosis, respectively.Conclusions This early monitoring study identified statistical signals for AEs following third doses of COVID-19 mRNA vaccination. Since this method is intended for screening purposes and generates crude results, results do not establish a causal association between the vaccines and AEs. FDA’s public health assessment remains consistent that the benefits of COVID-19 vaccination outweigh the risks of vaccination.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://bestinitiative.org/wp-content/uploads/2022/06/C19-Booster-Active-Monitoring-Protocol-Addendum-2022.pdf Funding StatementThere were no extra-institutional sources of funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe study protocol was publicly posted as referenced in the manuscript before data analyses, and related documents can be made available where needed by contacting the corresponding author. De-identified participant data will not be shared without approval from the data partners.